Skip to main content
ADCT
NYSE Life Sciences

ADC Therapeutics Files S-4 for Switzerland-to-Delaware Redomiciliation, Shareholder Vote Required

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.55
Mkt Cap
$197.885M
52W Low
$0.78
52W High
$4.98
52W Position info
99% above low
Off High info
69% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ADCT sits 99% above its 52-week low of $0.78.

Summary

ADC Therapeutics filed an S-4 proxy/prospectus for a proposed move of its legal domicile from Switzerland to Delaware, with a 1-for-1 share conversion and no change in share count. Shareholders must approve the redomiciliation, new charter and bylaws, and a discharge of directors; the deal lapses if not closed by June 30, 2027.


Key Events · Corporate Governance and Compliance · ADCT

  • Redomiciliation to Delaware Proposed

    The board unanimously approved moving incorporation from Switzerland to Delaware under PILA Article 163 and DGCL Section 388, continuing as ADC Therapeutics, Inc. with no liquidation or new legal entity.

  • One-for-One Share Conversion

    Each Swiss common share (CHF 0.08 par) automatically becomes one share of Delaware common stock ($0.10 par); the filing states the transaction will not dilute economic interest and outstanding share count is unchanged.

  • Authorized Capital Set at 394M Common

    The new charter authorizes 394,000,000 common shares and 3,000,000 preferred shares, with the board able to issue preferred and increase authorized common without a separate class vote.

  • Two-Thirds Vote Needed at EGM

    Redomiciliation and charter proposals require two-thirds of votes represented plus a majority of par value represented; the discharge proposal needs a simple majority. Meeting date and record date are blank in this preliminary filing.


Analysis · ADCT · Life Sciences

ADC Therapeutics wants to reincorporate from Switzerland to Delaware, and this S-4 is the proxy/prospectus that puts the move to a shareholder vote. The share count does not change — each Swiss share becomes one Delaware share — so this is not a dilution event. What does change is the rulebook: a classified board, no ability for stockholders to call special meetings or act by written consent, 66 2/3% supermajority requirements, and Section 203 takeover protections. Management's stated rationale centers on cost savings from ending duplicate Swiss and U.S. reporting, a clearer U.S. identity for investors and partners, and more flexibility to issue shares for capital raises — meaningful for a company that has repeatedly needed to raise cash. The deal lapses if not completed by June 30, 2027, and it still needs Swiss tax rulings, a Lex Koller ruling, creditor confirmation, SEC effectiveness and NYSE listing approval. Watch the special meeting date, which is left blank in this preliminary filing.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADCT was trading at $1.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $197.9M. The 52-week trading range was $0.78 to $4.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADCT - Latest Insights

ADCT
Nov 09, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.32 info
Change: -$0.426 (-24%) info
Market Cap: $189.894M info
ADCT
Nov 09, 2026, 7:30 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $1.32 info
Change: -$0.260 (-16%) info
Market Cap: $189.894M info
ADCT
Nov 04, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.32 info
Change: -$0.400 (-23%) info
Market Cap: $189.894M info
ADCT
Oct 13, 2026, 6:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.82
Real-time Price: $1.32 info
Change: -$0.500 (-27%) info
Market Cap: $189.894M info
ADCT
Oct 08, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $1.32 info
Change: -$0.010 (-0.75%) info
Market Cap: $189.894M info